Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Inventory (2016 - 2025)

Ani Pharmaceuticals' Change in Inventory history spans 14 years, with the latest figure at -$3.7 million for Q4 2025.

  • For Q4 2025, Change in Inventory fell 652.89% year-over-year to -$3.7 million; the TTM value through Dec 2025 reached $6.0 million, down 72.0%, while the annual FY2025 figure was $6.0 million, 72.0% down from the prior year.
  • Change in Inventory for Q4 2025 was -$3.7 million at Ani Pharmaceuticals, down from $8.2 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $11.6 million in Q2 2024 and bottomed at -$5.9 million in Q3 2021.
  • The 5-year median for Change in Inventory is $1.9 million (2022), against an average of $2.7 million.
  • The largest annual shift saw Change in Inventory soared 1635.58% in 2024 before it plummeted 652.89% in 2025.
  • A 5-year view of Change in Inventory shows it stood at $5.5 million in 2021, then skyrocketed by 70.52% to $9.5 million in 2022, then tumbled by 51.33% to $4.6 million in 2023, then plummeted by 85.34% to $675000.0 in 2024, then tumbled by 652.89% to -$3.7 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Change in Inventory are -$3.7 million (Q4 2025), $8.2 million (Q3 2025), and $908000.0 (Q2 2025).